Geron 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Syndax Pharmaceuticals 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

A visual target evaluation report for USP15, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.

Tango Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

ORIC Pharmaceuticals 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Nuvalent 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Fulcrum Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Agios Pharmaceuticals 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Disc Medicine 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.

Capricor Therapeutics 2026 BD opportunity scan: deramiocel and exosome pipeline, Nippon Shinyaku deal precedents, financial signals, IP risk and outreach priorities.

A focused 2026 clinical landscape deep dive into ChiCTR2600128129, evaluating SC-101 in Neoplasm Metastasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Cardurion Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.